
|Videos|November 2, 2018
Determining Treatment Options for Select Subsets of Neuroendocrine Tumors
Author(s)Thor Halfdanarson, MD
Thor Halfdanarson, MD, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
Advertisement
Thor Halfdanarson, MD, medical oncologist at Mayo Clinic, discusses his takeaway message on neuroendocrine tumors (NETs) at the 2018 ISGIO Annual Conference.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5








































